Market Overview:
The global drug induced ototoxicity treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of drug-induced ototoxicity, rising awareness about the available treatments, and technological advancements in hearing aids and cochlear implants. However, the high cost of treatment may restrain the growth of this market during the forecast period. The global drug induced ototoxicity treatment market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into alternative therapies, medications, hearing aids, cochlear implants, assistive listening devices (ALD’s), and others. The medications segment is expected to dominate this market during the forecast period owing to its large population base suffering from drug-induced ototoxicity. On the basis of application; it can be classified into cochlear drug-induced ototoxicity and vestibular drug-induced ototoxicity segments.
Product Definition:
Drug induced ototoxicity is a form of ototoxicity that is caused by medications. The most common medications to cause drug induced ototoxicity are antibiotics, chemotherapy agents, and diuretics. Treatment for drug induced ototoxicity includes stopping the use of the offending medication and treating any underlying causes. If the hearing loss is severe, then a hearing aid may be recommended.
Alternative Therapies:
The global alternative therapies, it's usage and growth factor in Drug Induced Ototoxicity (DIO) treatment market was valued at USD 6.5 billion in 2016 and is expected to grow at a CAGR of XX% during the forecast period.
Medications:
The global medications and its usage in Drug Induced Ototoxicity Treatment market size was valued at USD 1.5 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period.
Application Insights:
Based on application, the global market is segmented into cochlear drug-induced ototoxicity, vestibular drug-induced ototoxicity, tinnitus and hearing loss. The cochlear segment held the largest share in 2017 owing to high prevalence of hearing loss caused by damage to hair cells in the inner ear. According to research studies published in JCI Insight, around 30 million people suffer from hearing impairment due to noise exposure.
The growing aging population susceptible towards sound trauma and increasing incidence of noise induced hearing loss are some of the major factors driving this segment growth during forecast period.
Regional Analysis:
The global market is segmented as follows: North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW). The APAC region is expected to grow at a significant rate over the forecast period. This can be attributed to increasing R&D investments by various companies in this region and rising healthcare expenditure. Moreover, growing disposable income levels coupled with an increase in consumer awareness about early diagnosis will drive growth further.
The key countries considered for the study are China, Australia, India Japan South Korea Taiwan Thailand Philippines Indonesia Malaysia Singapore Sri Lanka Bangladesh Pakistan Iran Brazil Argentina Mexico Chile Colombia Venezuela Ecuador Peru Columbia U.
Growth Factors:
- Increasing incidence of drug induced ototoxicity
- Growing awareness about the treatment of drug induced ototoxicity
- Rising demand for novel and advanced drugs for the treatment of drug induced ototoxicity
- Technological advancements in the field of ototoxicity treatment 5. Growing number of clinical studies on drug induced ototoxicity
Scope Of The Report
Report Attributes
Report Details
Report Title
Drug Induced Ototoxicity Treatment Market Research Report
By Type
Alternative Therapies, Medications, Hearing Aids, Cochlear Implants, Assistive Listening Devices (ALD’s),
By Application
Cochlear Drug-Induced Ototoxicity, Vestibular Drug-Induced Ototoxicity,
By Companies
Advanced Bionics, Pfizer, Otonomy, Eli Lilly and Company, Sound Pharmaceuticals, WellSpring Pharmaceutical Corporation, Hoffmann-La Roche, Teva Pharmaceuticals, GlaxoSmithKline, Sonova Holding,
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Drug Induced Ototoxicity Treatment Market Report Segments:
The global Drug Induced Ototoxicity Treatment market is segmented on the basis of:
Types
Alternative Therapies, Medications, Hearing Aids, Cochlear Implants, Assistive Listening Devices (ALD’s),
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cochlear Drug-Induced Ototoxicity, Vestibular Drug-Induced Ototoxicity,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Advanced Bionics
- Pfizer
- Otonomy
- Eli Lilly and Company
- Sound Pharmaceuticals
- WellSpring Pharmaceutical Corporation
- Hoffmann-La Roche
- Teva Pharmaceuticals
- GlaxoSmithKline
- Sonova Holding
Highlights of The Drug Induced Ototoxicity Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alternative Therapies
- Medications
- Hearing Aids
- Cochlear Implants
- Assistive Listening Devices (ALD’s)
- By Application:
- Cochlear Drug-Induced Ototoxicity
- Vestibular Drug-Induced Ototoxicity
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drug Induced Ototoxicity Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Drug induced ototoxicity is a condition that can occur when a person takes medications or other substances that damage the ear. Treatment typically involves stopping the offending agent and treating any resulting hearing loss.
Some of the major players in the drug induced ototoxicity treatment market are Advanced Bionics, Pfizer, Otonomy, Eli Lilly and Company, Sound Pharmaceuticals, WellSpring Pharmaceutical Corporation, Hoffmann-La Roche, Teva Pharmaceuticals, GlaxoSmithKline, Sonova Holding.
The drug induced ototoxicity treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Drug Induced Ototoxicity Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Drug Induced Ototoxicity Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Drug Induced Ototoxicity Treatment Market - Supply Chain
4.5. Global Drug Induced Ototoxicity Treatment Market Forecast
4.5.1. Drug Induced Ototoxicity Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Drug Induced Ototoxicity Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Drug Induced Ototoxicity Treatment Market Absolute $ Opportunity
5. Global Drug Induced Ototoxicity Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Type
5.3.1. Alternative Therapies
5.3.2. Medications
5.3.3. Hearing Aids
5.3.4. Cochlear Implants
5.3.5. Assistive Listening Devices (ALDs)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Drug Induced Ototoxicity Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Application
6.3.1. Cochlear Drug-Induced Ototoxicity
6.3.2. Vestibular Drug-Induced Ototoxicity
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Drug Induced Ototoxicity Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Drug Induced Ototoxicity Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Drug Induced Ototoxicity Treatment Demand Share Forecast, 2019-2026
9. North America Drug Induced Ototoxicity Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Application
9.4.1. Cochlear Drug-Induced Ototoxicity
9.4.2. Vestibular Drug-Induced Ototoxicity
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Type
9.7.1. Alternative Therapies
9.7.2. Medications
9.7.3. Hearing Aids
9.7.4. Cochlear Implants
9.7.5. Assistive Listening Devices (ALDs)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Drug Induced Ototoxicity Treatment Demand Share Forecast, 2019-2026
10. Latin America Drug Induced Ototoxicity Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Application
10.4.1. Cochlear Drug-Induced Ototoxicity
10.4.2. Vestibular Drug-Induced Ototoxicity
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Type
10.7.1. Alternative Therapies
10.7.2. Medications
10.7.3. Hearing Aids
10.7.4. Cochlear Implants
10.7.5. Assistive Listening Devices (ALDs)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Drug Induced Ototoxicity Treatment Demand Share Forecast, 2019-2026
11. Europe Drug Induced Ototoxicity Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Application
11.4.1. Cochlear Drug-Induced Ototoxicity
11.4.2. Vestibular Drug-Induced Ototoxicity
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Type
11.7.1. Alternative Therapies
11.7.2. Medications
11.7.3. Hearing Aids
11.7.4. Cochlear Implants
11.7.5. Assistive Listening Devices (ALDs)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Drug Induced Ototoxicity Treatment Demand Share, 2019-2026
12. Asia Pacific Drug Induced Ototoxicity Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Application
12.4.1. Cochlear Drug-Induced Ototoxicity
12.4.2. Vestibular Drug-Induced Ototoxicity
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Type
12.7.1. Alternative Therapies
12.7.2. Medications
12.7.3. Hearing Aids
12.7.4. Cochlear Implants
12.7.5. Assistive Listening Devices (ALDs)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Drug Induced Ototoxicity Treatment Demand Share, 2019-2026
13. Middle East & Africa Drug Induced Ototoxicity Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Application
13.4.1. Cochlear Drug-Induced Ototoxicity
13.4.2. Vestibular Drug-Induced Ototoxicity
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Drug Induced Ototoxicity Treatment Market Size and Volume Forecast by Type
13.7.1. Alternative Therapies
13.7.2. Medications
13.7.3. Hearing Aids
13.7.4. Cochlear Implants
13.7.5. Assistive Listening Devices (ALDs)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Drug Induced Ototoxicity Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Drug Induced Ototoxicity Treatment Market: Market Share Analysis
14.2. Drug Induced Ototoxicity Treatment Distributors and Customers
14.3. Drug Induced Ototoxicity Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Advanced Bionics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Otonomy
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eli Lilly and Company
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sound Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. WellSpring Pharmaceutical Corporation
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hoffmann-La Roche
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Teva Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlaxoSmithKline
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sonova Holding
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
